KLRK1 and inflammatory bowel disease: However, while clinical trials assessing the efficacy of etrolizumab and anti-NKG2D showed sign of biological responses, the clinical results were negative, reflecting the complexity of intestinal mucosal immunology and the possibility that these treatments may be suitable for a subpopulation of IBD patients.